Search

Your search keyword '"Valvano,Luciana"' showing total 4 results
Start Over Author "Valvano,Luciana" Journal hematological oncology
4 results on '"Valvano,Luciana"'

1. Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand?

Author

D’Arena, Giovanni, primary, Sgambato, Alessandro, additional, Volpe, Silvestro, additional, Coppola, Giuseppe, additional, Amodeo, Rachele, additional, Tirino, Virginia, additional, D’Auria, Fiorella, additional, Statuto, Teodora, additional, Valvano, Luciana, additional, Pietrantuono, Giuseppe, additional, Deaglio, Silvia, additional, Efremov, Dimitar, additional, Laurenti, Luca, additional, and Aiello, Antonella, additional

Published
2022
Full Text
View/download PDF

2. Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand?

Author

D'Arena, Giovanni, Sgambato, Alessandro, Volpe, Silvestro, Coppola, Giuseppe, Amodeo, Rachele, Tirino, Virginia, D'Auria, Fiorella, Statuto, Teodora, Valvano, Luciana, Pietrantuono, Giuseppe, Deaglio, Silvia, Efremov, Dimitar, Laurenti, Luca, and Aiello, Antonella

Subjects
CHRONIC lymphocytic leukemia, CHRONIC diseases, CHRONIC leukemia, FLOW cytometry, TREATMENT effectiveness
Abstract

Measurable residual disease (MRD) has emerged as a relevant parameter of response to therapy in chronic lymphocytic leukemia (CLL). Although several methods have been developed, flow cytometry has emerged as the most useful and standardized approach to measure and quantify MRD. The improved sensitivity of MRD measurements has been paralleled by the development of more effective therapeutic strategies for CLL, increasing the applicability of MRD detection in this setting. Chemotherapy and chemoimmunotherapy have firstly demonstrated their ability to obtain a deep MRD. Combined targeted therapies are also demonstrating a high molecular response rate and prospective trials are exploring the role of MRD to guide the duration of treatment in this setting. In this review we briefly summarize what we have learned about MRD with emphasis on its flow cytometric detection. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

3. CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia

Author

D'Arena, Giovanni, primary, Vitale, Candida, additional, Rossi, Giovanni, additional, Coscia, Marta, additional, Omedè, Paola, additional, D'Auria, Fiorella, additional, Statuto, Teodora, additional, Valvano, Luciana, additional, Ciolli, Stefania, additional, Gilestro, Milena, additional, Molica, Stefano, additional, Bellesi, Silvia, additional, Topini, Giuseppe, additional, Panichi, Valentina, additional, Autore, Francesco, additional, Innocenti, Idanna, additional, Musto, Pellegrino, additional, Deaglio, Silvia, additional, Laurenti, Luca, additional, and Del Vecchio, Luigi, additional

Published
2018
Full Text
View/download PDF

4. Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand?

Author

Giovanni D’Arena, Alessandro Sgambato, Silvestro Volpe, Giuseppe Coppola, Rachele Amodeo, Virginia Tirino, Fiorella D’Auria, Teodora Statuto, Luciana Valvano, Giuseppe Pietrantuono, Silvia Deaglio, Dimitar Efremov, Luca Laurenti, Antonella Aiello, D’Arena, Giovanni, Sgambato, Alessandro, Volpe, Silvestro, Coppola, Giuseppe, Amodeo, Rachele, Tirino, Virginia, D’Auria, Fiorella, Statuto, Teodora, Valvano, Luciana, Pietrantuono, Giuseppe, Deaglio, Silvia, Efremov, Dimitar, Laurenti, Luca, and Aiello, Antonella

Subjects
measurable residual disease, Settore MED/15 - MALATTIE DEL SANGUE, Cancer Research, Oncology, flow cytometry, chronic lymphocytic leukemia, Hematology, General Medicine
Abstract

Measurable residual disease (MRD) has emerged as a relevant parameter of response to therapy in chronic lymphocytic leukemia (CLL). Although several methods have been developed, flow cytometry has emerged as the most useful and standardized approach to measure and quantify MRD. The improved sensitivity of MRD measurements has been paralleled by the development of more effective therapeutic strategies for CLL, increasing the applicability of MRD detection in this setting. Chemotherapy and chemoimmunotherapy have firstly demonstrated their ability to obtain a deep MRD. Combined targeted therapies are also demonstrating a high molecular response rate and prospective trials are exploring the role of MRD to guide the duration of treatment in this setting. In this review we briefly summarize what we have learned about MRD with emphasis on its flow cytometric detection.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results